Antiamoebic drugs for treating amoebic colitis

Abstract

Background Infection with the protozoan Entamoeba histolytica is common in low‐ and middle‐income countries, and up to 100,000 people with severe disease die every year. Adequate therapy for amoebic colitis is necessary to reduce illness, prevent development of complicated disease and extraintestinal spread, and decrease transmission. Objectives To evaluate antiamoebic drugs for treating amoebic colitis. Search methods We searched the available literature up to 22 March 2018. We searched the Cochrane Infectious Diseases Group Specialised Register, CENTRAL, MEDLINE, Embase, LILACS, m RCT, and conference proceedings. We contacted individual researchers, organizations, and pharmaceutical companies, and we checked reference lists. Selection criteria Randomized controlled trials of antiamoebic drugs given alone or in combination, compared with placebo or another antiamoebic drug, for treating adults and children with a diagnosis of amoebic colitis. Data collection and analysis Two review authors independently assessed the eligibility and methodological quality of trials and extracted and analysed the data. We calculated clinical and parasitological failure rates and rates of relapse and adverse events as risk ratios (RRs) with 95% confidence intervals (CIs), using a random‐effects model. We determined statistical heterogeneity and explored possible sources of heterogeneity using subgroup analyses. We carried out sensitivity analysis by using trial quality to assess the robustness of reported results. Main results In total, 41 trials (4999 participants) met the inclusion criteria of this review. In this update, we added four trials to the 37 trials included in the first published review version. Thirty trials were published over 20 years ago. Only one trial used adequate methods of randomization and allocation concealment, was blinded, and analysed all randomized participants. Only one trial used an E histolytica stool antigen test, and two trials used amoebic culture. Tinidazole may be more effective than metronidazole for reducing clinical failure (RR 0.28, 95% CI 0.15 to 0.51; 477 participants, eight trials; low‐certainty evidence) and is probably associated with fewer adverse events (RR 0.65, 95% CI 0.46 to 0.92; 477 participants, 8 trials; moderate‐certainty evidence). Compared with metronidazole, combination therapy may result in fewer parasitological failures (RR 0.36, 95% CI 0.15 to 0.86; 720 participants, 3 trials; low‐certainty evidence), but we are uncertain which combination is more effective than another. Evidence is insufficient to allow conclusions regarding the efficacy of other antiamoebic drugs. Authors' conclusions Compared with metronidazole, tinidazole may be more effective in reducing clinical failur...

Persistent abdominal pain of a middle aged old female– Think of Amoebic Colitis

“…Cröhn's disease involves the small and large intestine in patches with typical skip areas and transmural involvement is also common. 4,5 In the index case, no skip area, creeping fat or fistula was noted. Microscopically, there were no features of activity or chronicity to suggest a possibility of inflammatory bowel disease.…”

“…It is usually common in immunocopmpromised individuals, pregnant women and malnourished children. 4 Diffuse ulceration of the ileum and colon with perforation and serositis can occur due to inflammatory bowel disease, ischaemic colitis, vasculitis and infective causes. In this context, gross and microscopic examination of the vessels is an extremely important adjunct to a proper diagnosis.…”

Development of amoebic liver abscess in early pregnancy years after initial amoebic exposure: a case report

“…Metronidazole and the structurally similar tinidazole are the therapeutic agents used for treatment of acute infection with E. histolytica [ 34 ]. Metronidazole is the treatment of choice for pregnant women [ 35 ].…”

Entamoeba histolytica and amoebic liver abscess in northern Sri Lanka: a public health problem

“…Patients are expected to commence on luminal medications to eradicate intestinal colonization in the cecum, such as paromomycin (25-30 mg/kg orally three times daily for 7 days) [63,109]. While there is strong evidence demonstrating that monotherapy is often inadequate in invasive disease, it is not standard practice in SLK, due to being in a resource-limited setting [110]. Other treatment approaches such as ultrasonography-guided drainage of ALA remain controversial, with no difference in mortality rates between medical therapy and aspiration of abscesses in uncomplicated ALA [49,52].…”